Combining the 4Kscore or ExoDx with multiparametric MRI appears to be the optimal strategy for detecting high-grade prostate cancer, a study from the University of California, San Francisco suggests. However, it is reasonable to consider biomarker testing only in patients who want to avoid biopsy, said first author Claire M. de la Calle, MD.
SUO Annual Meeting
Clinicians are taught that renal cell carcinoma is radioresistant, but modalities such as stereotactic body radiation therapy (SBRT) can be safe and efficacious in certain patients with RCC. In this interview, Vitaly Margulis, MD, outlines the advantages of SBRT and offers a preview of the RADVAX trial, which combines radiotherapy and immunotherapy.
The Cancer Genome Atlas (TCGA) has provided a “complete genomic roadmap” of muscle-invasive bladder cancer, according to Seth P. Lerner, MD, co-chair of the Analysis Working Group of the TCGA program for muscle-invasive bladder cancer. Dr. Lerner talks to Urology Times about the clinical relevance of the TCGA’s findings, possible implications for upper tract disease, and what further research is needed.
The introduction of targeted therapies and immunotherapies has generated uncertainty regarding the role of the cytoreductive nephrectomy in the treatment of metastatic renal cell carcinoma. In this interview, Hyung L. Kim, MD, discusses the recent CARMENA and SURTIME clinical trials, and outlines the upcoming SWOG-1931 trial.
In a pivotal phase III study, more than half of patients with high-grade nonmuscle-invasive bladder cancer (carcinoma in situ ± Ta/T1) receiving nadofaragene firadenovec achieved a complete response at 3 months, reported lead author Colin P.N. Dinney, MD.
Christopher Sweeney, MBBS, outlines a handful of important questions to ask when deciding which systemic therapy to select for which patient with metastatic hormone-sensitive prostate cancer.
“I think it’s time to realize that there are other options besides cystectomy, and that the other options should at least be discussed and entertained,” says Alexandre Zlotta, MD, PhD, in this video.
“Over the past few decades, the rate of active surveillance has been around 10%. Now in recent years, the rate of active surveillance is 55% across the U.S. So times are changing," says Sigrid Carlsson, MD, PhD, MPH, in this interview.
In this video, Viraj Master, MD, offers the latest evidence and his recommendations for managing synchronous and metachronous disease in the face of renal cell carcinoma, including the role of metastasectomy.
In this video interview with Urology Times, Arjun V. Balar, MD, PhD, discusses the current role of PD-1 inhibitors, their mechanism of action, and his own impression of recently presented phase II study data.